LifePlan Financial LLC Acquires New Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

LifePlan Financial LLC purchased a new stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 708 shares of the medical research company's stock, valued at approximately $352,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of TMO. Ameritas Advisory Services LLC increased its stake in Thermo Fisher Scientific by 3.5% in the 1st quarter. Ameritas Advisory Services LLC now owns 3,796 shares of the medical research company's stock worth $1,903,000 after buying an additional 127 shares in the last quarter. Amalgamated Bank grew its position in shares of Thermo Fisher Scientific by 1.4% during the first quarter. Amalgamated Bank now owns 74,442 shares of the medical research company's stock worth $37,042,000 after purchasing an additional 995 shares in the last quarter. Verity Asset Management Inc. raised its stake in Thermo Fisher Scientific by 113.1% during the 1st quarter. Verity Asset Management Inc. now owns 1,040 shares of the medical research company's stock valued at $518,000 after purchasing an additional 552 shares during the period. Citizens National Bank Trust Department grew its holdings in Thermo Fisher Scientific by 4.0% during the 1st quarter. Citizens National Bank Trust Department now owns 4,883 shares of the medical research company's stock valued at $2,430,000 after buying an additional 188 shares in the last quarter. Finally, Avidian Wealth Enterprises LLC raised its position in shares of Thermo Fisher Scientific by 16.6% during the first quarter. Avidian Wealth Enterprises LLC now owns 1,321 shares of the medical research company's stock valued at $657,000 after buying an additional 188 shares during the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Stock Performance

Shares of NYSE TMO traded up $0.49 during midday trading on Thursday, reaching $428.25. 1,359,321 shares of the stock were exchanged, compared to its average volume of 1,967,269. The company has a quick ratio of 1.38, a current ratio of 1.77 and a debt-to-equity ratio of 0.64. The firm has a 50-day simple moving average of $409.06 and a two-hundred day simple moving average of $481.30. Thermo Fisher Scientific Inc. has a twelve month low of $385.46 and a twelve month high of $627.88. The firm has a market cap of $161.66 billion, a price-to-earnings ratio of 25.12, a PEG ratio of 2.24 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, beating analysts' consensus estimates of $5.10 by $0.05. Thermo Fisher Scientific had a net margin of 15.19% and a return on equity of 17.15%. The company had revenue of $10.36 billion during the quarter, compared to analysts' expectations of $10.23 billion. During the same quarter in the previous year, the company earned $5.11 earnings per share. The firm's revenue for the quarter was up .2% on a year-over-year basis. As a group, analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 15th. Shareholders of record on Friday, June 13th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 0.40%. The ex-dividend date is Friday, June 13th. Thermo Fisher Scientific's payout ratio is 10.09%.

Analysts Set New Price Targets

TMO has been the subject of a number of research analyst reports. Scotiabank cut their price objective on Thermo Fisher Scientific from $650.00 to $605.00 and set a "sector perform" rating for the company in a research report on Friday, April 25th. UBS Group lowered their price target on shares of Thermo Fisher Scientific from $715.00 to $500.00 and set a "buy" rating for the company in a report on Thursday, April 24th. Robert W. Baird lowered their price objective on Thermo Fisher Scientific from $603.00 to $573.00 and set an "outperform" rating for the company in a research note on Thursday, April 24th. Royal Bank Of Canada lowered their price target on Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating for the company in a research report on Thursday, April 24th. Finally, Wall Street Zen raised shares of Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research note on Wednesday, May 21st. Four analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $604.05.

Insider Activity

In related news, EVP Gianluca Pettiti sold 300 shares of the company's stock in a transaction dated Monday, April 28th. The shares were sold at an average price of $429.93, for a total transaction of $128,979.00. Following the completion of the transaction, the executive vice president owned 23,167 shares in the company, valued at $9,960,188.31. This represents a 1.28% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.33% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.